(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Abraxas Petroleum Corporation, Advaxis, and Avid Technology.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Abraxas Petroleum Corporation (AXAS) | 0.03 | 25.39% | 2023-05-24 13:41:11 |
| 2 | Advaxis (ADXS) | 0.95 | 18.75% | 2023-05-24 03:12:07 |
| 3 | Avid Technology (AVID) | 24.06 | 17.54% | 2023-05-24 13:17:07 |
| 4 | AcelRx Pharmaceuticals (ACRX) | 0.89 | 15.89% | 2023-05-24 01:15:07 |
| 5 | Nautilus (NLS) | 1.33 | 14.66% | 2023-05-24 13:58:48 |
| 6 | Agile Therapeutics (AGRX) | 4.01 | 8.67% | 2023-05-24 04:42:07 |
| 7 | Palo Alto Networks (PANW) | 202.88 | 6.93% | 2023-05-24 13:59:19 |
| 8 | Amyris (AMRS) | 0.74 | 5.47% | 2023-05-24 07:23:08 |
| 9 | NeuroMetrix (NURO) | 1.08 | 4.85% | 2023-05-24 13:51:11 |
| 10 | Atossa Therapeutics (ATOS) | 0.87 | 4.16% | 2023-05-24 12:23:09 |
The three biggest losers today are Virgin Galactic, Aptose Biosciences, and Adamis Pharmaceuticals Corporation.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Virgin Galactic (SPCE) | 4.29 | -13.08% | 2023-05-24 14:02:38 |
| 2 | Aptose Biosciences (APTO) | 0.42 | -11.66% | 2023-05-24 09:12:07 |
| 3 | Adamis Pharmaceuticals Corporation (ADMP) | 2.82 | -11.6% | 2023-05-24 01:55:31 |
| 4 | Nio (NIO) | 7.89 | -9.84% | 2023-05-24 13:58:42 |
| 5 | Affimed N.V. (AFMD) | 0.97 | -9.69% | 2023-05-24 03:47:08 |
| 6 | Ascent Solar Technologies (ASTI) | 0.15 | -8.65% | 2023-05-24 11:12:07 |
| 7 | Tattooed Chef (TTCF) | 0.61 | -8.51% | 2023-05-24 14:03:24 |
| 8 | Upland Software (UPLD) | 3.02 | -8.36% | 2023-05-24 14:43:18 |
| 9 | Analog Devices (ADI) | 172.35 | -8.29% | 2023-05-24 13:50:15 |
| 10 | Inovio Pharmaceuticals (INO) | 0.61 | -8.19% | 2023-05-24 10:55:29 |
Winners today
1. Abraxas Petroleum Corporation (AXAS) – 25.39%
Abraxas Petroleum Corporation, an independent energy company, engages in the acquisition, exploration, exploitation, development, and production of oil and gas properties in the United States. The company operates oil and gas assets in the Permian/Delaware Basin and the Rocky Mountain regions. As of December 31, 2021, its estimated net proved reserves were 14.8 million barrels of oil equivalent. The company was founded in 1977 and is based in San Antonio, Texas.
NASDAQ ended the session with Abraxas Petroleum Corporation jumping 25.39% to $0.03 on Wednesday while NASDAQ fell 0.61% to $12,484.16.
Earnings Per Share
As for profitability, Abraxas Petroleum Corporation has a trailing twelve months EPS of $0.07.
PE Ratio
Abraxas Petroleum Corporation has a trailing twelve months price to earnings ratio of 0.46. Meaning, the purchaser of the share is investing $0.46 for every dollar of annual earnings.
More news about Abraxas Petroleum Corporation.
2. Advaxis (ADXS) – 18.75%
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
NASDAQ ended the session with Advaxis rising 18.75% to $0.95 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ slid 0.61% to $12,484.16, following the last session’s downward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, Advaxis has a trailing twelve months EPS of $-10.05.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -229.97%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 90.8%, now sitting on 692k for the twelve trailing months.
More news about Advaxis.
3. Avid Technology (AVID) – 17.54%
Avid Technology, Inc., together with its subsidiaries, develops, markets, sells, and supports software and integrated solutions for video and audio content creation, management, and distribution worldwide. The company's video products and solutions include the Media Composer, a cloud-enabled solution used to edit video content; Avid NEXIS shared storage systems; Maestro solutions for the integration of virtual sets, augmented reality, and video wall control into existing workflows; AirSpeed 5000 and AirSpeed 5500 on-air server solutions; and MediaCentral, a media production suite. Its audio products and solutions comprise Pro Tools digital audio software solutions to facilitate the audio production process; Sibelius solution to create, edit, and publish musical scores; S6 line of complementary control surfaces and consoles; S1 and S4 audio control surfaces; and VENUE | S6L live sound system for mixing audio for live sound reinforcement. The company also provides Avid Link, a mobile application to connect with other artists, producers, mixers, composers, editors, videographers, movie makers, and graphic designers; FastServe video server that assists broadcasters in making the move to UHD and IP based workflows with a new and modular architecture; and hardware products, such as I/O devices, interfaces, and audio and video processing equipment. In addition, it offers various maintenance contracts and support services; professional services, such as workflow design and consulting, program and project management, system installation and commissioning, and custom development and role-based product level training; and public and private training to customers and alliance partners, as well as develops and licenses curriculum content for use by third party Avid Learning partners to deliver training to customers, users, and alliance partners. The company was incorporated in 1987 and is headquartered in Burlington, Massachusetts.
NASDAQ ended the session with Avid Technology jumping 17.54% to $24.06 on Wednesday while NASDAQ slid 0.61% to $12,484.16.
Earnings Per Share
As for profitability, Avid Technology has a trailing twelve months EPS of $0.98.
PE Ratio
Avid Technology has a trailing twelve months price to earnings ratio of 24.55. Meaning, the purchaser of the share is investing $24.55 for every dollar of annual earnings.
Moving Average
Avid Technology’s value is way below its 50-day moving average of $27.85 and way below its 200-day moving average of $27.25.
Yearly Top and Bottom Value
Avid Technology’s stock is valued at $24.06 at 17:32 EST, way under its 52-week high of $33.41 and way higher than its 52-week low of $19.78.
Volume
Today’s last reported volume for Avid Technology is 3807570 which is 1001.24% above its average volume of 345754.
More news about Avid Technology.
4. AcelRx Pharmaceuticals (ACRX) – 15.89%
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
NASDAQ ended the session with AcelRx Pharmaceuticals jumping 15.89% to $0.89 on Wednesday while NASDAQ fell 0.61% to $12,484.16.
Earnings Per Share
As for profitability, AcelRx Pharmaceuticals has a trailing twelve months EPS of $5.68.
PE Ratio
AcelRx Pharmaceuticals has a trailing twelve months price to earnings ratio of 0.16. Meaning, the purchaser of the share is investing $0.16 for every dollar of annual earnings.
Earnings Before Interest, Taxes, Depreciation, and Amortization
AcelRx Pharmaceuticals’s EBITDA is 1.73.
Yearly Top and Bottom Value
AcelRx Pharmaceuticals’s stock is valued at $0.89 at 17:32 EST, way under its 52-week high of $7.60 and way higher than its 52-week low of $0.55.
Volume
Today’s last reported volume for AcelRx Pharmaceuticals is 113345 which is 45.85% below its average volume of 209355.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 105.2% and positive 50% for the next.
More news about AcelRx Pharmaceuticals.
5. Nautilus (NLS) – 14.66%
Nautilus, Inc., a fitness solutions company, designs, develops, sources, and markets cardio and strength fitness products, and related accessories for consumer and commercial use in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company operates in two segments, Direct and Retail. It offers specialized cardio products, treadmills, ellipticals, bike products, home gyms, dumbbells, barbells, and kettlebells primarily under the Nautilus, Bowflex, Octane Fitness, and Schwinn brands, as well as fitness digital platform under the JRNY brand. In addition, it engages in licensing its brands and intellectual properties. The company offers its products directly to consumers through television advertising, social media, websites, and catalogs; and through a network of retail companies consisting of sporting goods stores, online retailers, electronics stores, furniture stores, and large-format and warehouse stores, as well as specialty retailers and independent bike dealers. Nautilus, Inc. was founded in 1986 and is headquartered in Vancouver, Washington.
NYSE ended the session with Nautilus rising 14.66% to $1.33 on Wednesday, following the last session’s downward trend. NYSE dropped 0.98% to $15,022.89, after three consecutive sessions in a row of losses, on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, Nautilus has a trailing twelve months EPS of $-3.37.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -79.46%.
Yearly Top and Bottom Value
Nautilus’s stock is valued at $1.33 at 17:32 EST, way under its 52-week high of $2.69 and way higher than its 52-week low of $1.12.
Previous days news about Nautilus
- Nautilus (nls) reports Q4 loss, tops revenue estimates. According to Zacks on Tuesday, 23 May, "While Nautilus has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
More news about Nautilus.
6. Agile Therapeutics (AGRX) – 8.67%
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
NASDAQ ended the session with Agile Therapeutics rising 8.67% to $4.01 on Wednesday, following the last session’s upward trend. NASDAQ fell 0.61% to $12,484.16, following the last session’s downward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, Agile Therapeutics has a trailing twelve months EPS of $90.54.
PE Ratio
Agile Therapeutics has a trailing twelve months price to earnings ratio of 0.04. Meaning, the purchaser of the share is investing $0.04 for every dollar of annual earnings.
Sales Growth
Agile Therapeutics’s sales growth is 91.9% for the current quarter and 75.5% for the next.
Yearly Top and Bottom Value
Agile Therapeutics’s stock is valued at $4.01 at 17:32 EST, way under its 52-week high of $141.00 and way above its 52-week low of $3.36.
Moving Average
Agile Therapeutics’s value is way below its 50-day moving average of $8.05 and way below its 200-day moving average of $13.01.
More news about Agile Therapeutics.
7. Palo Alto Networks (PANW) – 6.93%
Palo Alto Networks, Inc. provides cybersecurity solutions worldwide. The company offers firewall appliances and software; Panorama, a security management solution for the control of firewall appliances and software deployed on a customer's network, as well as their instances in public or private cloud environments, as a virtual or a physical appliance; and virtual system upgrades, which are available as extensions to the virtual system capacity that ships with physical appliances. It also provides subscription services covering the areas of threat prevention, malware and persistent threat, URL filtering, laptop and mobile device protection, and firewall; and DNS security, Internet of Things security, SaaS security API, and SaaS security inline, as well as threat intelligence, and data loss prevention. In addition, the company offers cloud security, secure access, security operations, and threat intelligence and cyber security consulting; professional services, including architecture design and planning, implementation, configuration, and firewall migration; education services, such as certifications, as well as online and in-classroom training; and support services. Palo Alto Networks, Inc. sells its products and services through its channel partners, as well as directly to medium to large enterprises, service providers, and government entities operating in various industries, including education, energy, financial services, government entities, healthcare, Internet and media, manufacturing, public sector, and telecommunications. The company was incorporated in 2005 and is headquartered in Santa Clara, California.
NYSE ended the session with Palo Alto Networks rising 6.93% to $202.88 on Wednesday while NYSE dropped 0.98% to $15,022.89.
Earnings Per Share
As for profitability, Palo Alto Networks has a trailing twelve months EPS of $0.08.
PE Ratio
Palo Alto Networks has a trailing twelve months price to earnings ratio of 2536. Meaning, the purchaser of the share is investing $2536 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.1%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Palo Alto Networks’s stock is considered to be oversold (<=20).
More news about Palo Alto Networks.
8. Amyris (AMRS) – 5.47%
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
NASDAQ ended the session with Amyris rising 5.47% to $0.74 on Wednesday while NASDAQ slid 0.61% to $12,484.16.
Earnings Per Share
As for profitability, Amyris has a trailing twelve months EPS of $-2.37.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 171.4% and 45.5%, respectively.
Volume
Today’s last reported volume for Amyris is 4653840 which is 6.23% below its average volume of 4963270.
Sales Growth
Amyris’s sales growth is 324.7% for the current quarter and 20.9% for the next.
Yearly Top and Bottom Value
Amyris’s stock is valued at $0.74 at 17:32 EST, way below its 52-week high of $4.86 and way above its 52-week low of $0.55.
More news about Amyris.
9. NeuroMetrix (NURO) – 4.85%
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
NASDAQ ended the session with NeuroMetrix rising 4.85% to $1.08 on Wednesday, following the last session’s downward trend. NASDAQ slid 0.61% to $12,484.16, following the last session’s downward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.75.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.76%.
More news about NeuroMetrix.
10. Atossa Therapeutics (ATOS) – 4.16%
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
NASDAQ ended the session with Atossa Therapeutics rising 4.16% to $0.87 on Wednesday while NASDAQ dropped 0.61% to $12,484.16.
Earnings Per Share
As for profitability, Atossa Therapeutics has a trailing twelve months EPS of $-0.22.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.91%.
Yearly Top and Bottom Value
Atossa Therapeutics’s stock is valued at $0.87 at 17:32 EST, way under its 52-week high of $1.36 and way higher than its 52-week low of $0.50.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 20% and a negative 16.7%, respectively.
Moving Average
Atossa Therapeutics’s value is way above its 50-day moving average of $0.70 and way higher than its 200-day moving average of $0.78.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Atossa Therapeutics’s EBITDA is 8.99.
More news about Atossa Therapeutics.
Losers Today
1. Virgin Galactic (SPCE) – -13.08%
Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico.
NYSE ended the session with Virgin Galactic falling 13.08% to $4.29 on Wednesday, after four sequential sessions in a row of gains. NYSE slid 0.98% to $15,022.89, after three sequential sessions in a row of losses, on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, Virgin Galactic has a trailing twelve months EPS of $-2.37.
More news about Virgin Galactic.
2. Aptose Biosciences (APTO) – -11.66%
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
NASDAQ ended the session with Aptose Biosciences dropping 11.66% to $0.42 on Wednesday, after two successive sessions in a row of gains. NASDAQ slid 0.61% to $12,484.16, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, Aptose Biosciences has a trailing twelve months EPS of $-0.47.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -96.45%.
More news about Aptose Biosciences.
3. Adamis Pharmaceuticals Corporation (ADMP) – -11.6%
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
NASDAQ ended the session with Adamis Pharmaceuticals Corporation dropping 11.6% to $2.82 on Wednesday, after five successive sessions in a row of losses. NASDAQ dropped 0.61% to $12,484.16, following the last session’s downward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, Adamis Pharmaceuticals Corporation has a trailing twelve months EPS of $-10.21.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -784.96%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Adamis Pharmaceuticals Corporation’s EBITDA is 1.16.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25.9%, now sitting on 5.05M for the twelve trailing months.
Sales Growth
Adamis Pharmaceuticals Corporation’s sales growth is 2.8% for the ongoing quarter and 85.6% for the next.
Moving Average
Adamis Pharmaceuticals Corporation’s value is way under its 50-day moving average of $6.43 and way under its 200-day moving average of $12.82.
More news about Adamis Pharmaceuticals Corporation.
4. Nio (NIO) – -9.84%
NIO Inc. designs, develops, manufactures, and sells smart electric vehicles in China. It offers five and six-seater electric SUVs, as well as smart electric sedans. The company also offers power solutions, including Power Home, a home charging solution; Power Swap, a battery swapping service; Power Charger and Destination Charger; Power Mobile, a mobile charging service through charging vans; Power Map, an application that provides access to a network of public chargers and their real-time information; and One Click for Power valet service. In addition, it provides repair, maintenance, and bodywork services through its NIO service centers and authorized third-party service centers; statutory and third-party liability insurance, and vehicle damage insurance through third-party insurers; repair and routine maintenance; courtesy vehicle services; roadside assistance; data packages; and auto financing and financial leasing services. Further, the company involved in the provision of energy and service packages to its users; design and technology development activities; manufacture of e-powertrains, battery packs, and components; and sales and after sales management activities. Additionally, it offers NIO Certified, a used vehicle inspection, evaluation, acquisition, and sales service. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was incorporated in 2014 and is headquartered in Shanghai, China.
NYSE ended the session with Nio sliding 9.84% to $7.89 on Wednesday, following the last session’s downward trend. NYSE slid 0.98% to $15,022.89, after three successive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.
: nio, Tesla stocks fall in wake of disappointing Xpeng resultsShares of Nio Inc. slumped 1.9% in premarket trading Wednesday, weighed down by rival China-based electric vehicle maker XPeng Inc. reported fell 1.2%, as the EV giant generated 21% of its first-quarter revenue from China.
Earnings Per Share
As for profitability, Nio has a trailing twelve months EPS of $-1.38.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.79%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nio’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 62.2%, now sitting on 49.27B for the twelve trailing months.
Previous days news about Nio
- : nio shares rally more than 8%, lifting automaker’s stocks. According to MarketWatch on Monday, 22 May, "U.S.-listed shares of Chinese EV maker Nio Inc. rallied more than 8% Monday, extending their winning streak a second day and outperforming the broader equity indexes by a large margin. ", "Gains for Nio also lifted the American depositary shares of XPeng Inc. , which gained more than 4%. "
- Autoliv (alv) & nio unite to develop safety products for EVs. According to Zacks on Monday, 22 May, "Per the agreement, AutoLiv and Nio will design safety products for electric vehicles, focusing primarily on sustainable technologies. ", "Nio’s vice president of Supply Chain Development, Yu Pan, hinted that the cooperation between AutoLive and Nio has the potential to extend to more areas as both companies are committed to improving the driving experience of all users across the globe."
More news about Nio.
5. Affimed N.V. (AFMD) – -9.69%
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
NASDAQ ended the session with Affimed N.V. falling 9.69% to $0.97 on Wednesday while NASDAQ slid 0.61% to $12,484.16.
Earnings Per Share
As for profitability, Affimed N.V. has a trailing twelve months EPS of $-0.64.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.55%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Affimed N.V.’s EBITDA is 1.04.
Moving Average
Affimed N.V.’s value is way above its 50-day moving average of $0.82 and way under its 200-day moving average of $1.53.
Yearly Top and Bottom Value
Affimed N.V.’s stock is valued at $0.97 at 17:32 EST, way below its 52-week high of $3.40 and way above its 52-week low of $0.55.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 50% and a negative 61.5%, respectively.
Previous days news about Affimed N.V.
- Affimed n.v. (afmd) reports Q1 loss, lags revenue estimates. According to Zacks on Tuesday, 23 May, "While Affimed N.V. Has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?", "Ahead of this earnings release, the estimate revisions trend for Affimed N.V. Mixed. "
More news about Affimed N.V..
6. Ascent Solar Technologies (ASTI) – -8.65%
Ascent Solar Technologies, Inc. designs, manufactures, and sells copper-indium-gallium-diselenide photovoltaic products for aerospace, defense, emergency management, and consumer/OEM applications. It offers outdoor solar chargers. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies. Ascent Solar Technologies, Inc. was incorporated in 2005 and is based in Thornton, Colorado.
NASDAQ ended the session with Ascent Solar Technologies sliding 8.65% to $0.15 on Wednesday while NASDAQ slid 0.61% to $12,484.16.
Earnings Per Share
As for profitability, Ascent Solar Technologies has a trailing twelve months EPS of $-0.62.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ascent Solar Technologies’s EBITDA is 6.39.
More news about Ascent Solar Technologies.
7. Tattooed Chef (TTCF) – -8.51%
Tattooed Chef, Inc., a plant-based food company, produces and sells a portfolio of frozen foods. It supplies plant-based products to retailers in the United States. The company offers ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, cauliflower crust pizza, wood fire crusted pizza, handheld burritos, and bars and quesadillas. Its products are available in private label and Tattooed Chef brand name in the frozen food section of retail food stores, as well as online. Tattooed Chef, Inc. is headquartered in Paramount, California.
NASDAQ ended the session with Tattooed Chef dropping 8.51% to $0.61 on Wednesday while NASDAQ dropped 0.61% to $12,484.16.
Earnings Per Share
As for profitability, Tattooed Chef has a trailing twelve months EPS of $-1.17.
Sales Growth
Tattooed Chef’s sales growth is negative 7.9% for the present quarter and negative 25.9% for the next.
Volatility
Tattooed Chef’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.30%, a negative 5.23%, and a positive 5.69%.
Tattooed Chef’s highest amplitude of average volatility was 2.92% (last week), 7.56% (last month), and 5.69% (last quarter).
Volume
Today’s last reported volume for Tattooed Chef is 922111 which is 11.05% below its average volume of 1036720.
More news about Tattooed Chef.
8. Upland Software (UPLD) – -8.36%
Upland Software, Inc. provides cloud-based enterprise work management software in the United States, the United Kingdom, Canada, and internationally. It offers a family of software applications under the Upland brand in the areas of marketing, sales, contact center, project management, information technology, business operations, and human resources and legal. The company also provides professional services, such as implementation, data extraction, integration and configuration, and training services, as well as customer support services. It serves large global corporations, various government agencies, and small and medium-sized businesses, as well as financial, consulting, technology, manufacturing, media, telecommunication, political, healthcare, life sciences, and retail and hospitality sectors. The company was formerly known as Silverback Enterprise Group, Inc. and changed its name to Upland Software, Inc. in November 2013. Upland Software, Inc. was incorporated in 2010 and is headquartered in Austin, Texas.
NASDAQ ended the session with Upland Software falling 8.36% to $3.02 on Wednesday while NASDAQ fell 0.61% to $12,484.16.
Earnings Per Share
As for profitability, Upland Software has a trailing twelve months EPS of $-6.16.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.96%.
Volume
Today’s last reported volume for Upland Software is 184823 which is 61.46% below its average volume of 479642.
Revenue Growth
Year-on-year quarterly revenue growth declined by 2.1%, now sitting on 315.64M for the twelve trailing months.
Yearly Top and Bottom Value
Upland Software’s stock is valued at $3.02 at 17:32 EST, way below its 52-week high of $16.33 and higher than its 52-week low of $2.89.
More news about Upland Software.
9. Analog Devices (ADI) – -8.29%
Analog Devices, Inc. designs, manufactures, tests, and markets integrated circuits (ICs), software, and subsystems that leverage analog, mixed-signal, and digital signal processing technologies. The company provides data converter products, which translate real-world analog signals into digital data, as well as translates digital data into analog signals; power management and reference products for power conversion, driver monitoring, sequencing, and energy management applications in the automotive, communications, industrial, and high-end consumer markets; and power ICs that include performance, integration, and software design simulation tools for accurate power supply designs. It also offers high-performance amplifiers to condition analog signals; and radio frequency and microwave ICs to support cellular infrastructure; and micro-electro-mechanical systems technology solutions, including accelerometers used to sense acceleration, gyroscopes for sense rotation, inertial measurement units to sense multiple degrees of freedom, and broadband switches for radio and instrument systems, as well as isolators. In addition, the company provides digital signal processing and system products for high-speed numeric calculations. It serves clients in the industrial, automotive, consumer, instrumentation, aerospace, and communications markets through a direct sales force, third-party distributors, and independent sales representatives in the United States, rest of North and South America, Europe, Japan, China, and rest of Asia, as well as through its Website. Analog Devices, Inc. was incorporated in 1965 and is headquartered in Wilmington, Massachusetts.
NASDAQ ended the session with Analog Devices sliding 8.29% to $172.35 on Wednesday, following the last session’s downward trend. NASDAQ slid 0.61% to $12,484.16, following the last session’s downward trend on what was a somewhat bearish trend trading session today.
: analog devices stock falls after earnings as CEO says revenue could ‘moderate’Shares of Analog Devices Inc. were falling about 5% in premarket trading Wednesday after the chip company beat expectations with the results for its latest quarter but fell short with its profit outlook and said revenue could moderate in the second half of the year.
Analog devices (adi) tops Q2 earnings and revenue estimatesWhile Analog Devices has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
Analog devices (adi) Q2 earnings: taking a look at key metrics versus estimatesHere is how Analog Devices performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Earnings Per Share
As for profitability, Analog Devices has a trailing twelve months EPS of $6.6.
PE Ratio
Analog Devices has a trailing twelve months price to earnings ratio of 26.11. Meaning, the purchaser of the share is investing $26.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.27%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 14.6% and 4%, respectively.
Moving Average
Analog Devices’s value is below its 50-day moving average of $186.28 and higher than its 200-day moving average of $168.71.
Previous days news about Analog Devices
- What's in the offing for analog devices (adi) in Q2 earnings?. According to Zacks on Tuesday, 23 May, "Our proven model does not conclusively predict an earnings beat for Analog Devices this time around. "
More news about Analog Devices.
10. Inovio Pharmaceuticals (INO) – -8.19%
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
NASDAQ ended the session with Inovio Pharmaceuticals sliding 8.19% to $0.61 on Wednesday, following the last session’s downward trend. NASDAQ fell 0.61% to $12,484.16, following the last session’s downward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-0.97.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Inovio Pharmaceuticals’s EBITDA is -2.86.
Volume
Today’s last reported volume for Inovio Pharmaceuticals is 11574300 which is 97.07% above its average volume of 5873180.
More news about Inovio Pharmaceuticals.
Stay up to date with our winners and losers daily report
